Develops vectorised antibody treatments for neurodegenerative diseases using AAV delivery.
Founders
Sander van Deventer(Netherlands · ♂)— A gene-therapy pioneer behind Remicade and Glybera and co-founder of uniQure, he co-founded and led VectorY to develop AAV-delivered vectorized antibodies for neurodegenerative disease.
Pavlina Konstantinova(♀)— A gene therapy and vector development scientist who co-founded VectorY to advance its AAV antibody platform.
Barbara Sanders(♀)— Brought over a decade of viral-vector development experience from pharma and biotech to co-found VectorY.
Anthony Newcombe(UK · ♂)— A biopharmaceutical manufacturing leader from Samsung Biologics, he co-founded VectorY in 2020 as COO to industrialize its AAV vectorized-antibody platform.
Team & hubs
Funding history
Date
Round
Amount
Nov 2023
Series A
Amsterdam biotech VectorY Therapeutics raised a EUR129M Series A co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund.
$138M
Investors
Tap an investor to see what else they have backed.